Examining the safety and efficacy of a non-animal cross-linked hyaluronic acid

Abstract Background Nanomaterials of curcumin with hyaluronic acid have gained a lot of attention for potential therapeutic applications of curcumin and hyaluronic acid with or without other additional drugs. Overall studies of curcumin and hyaluronic acid show that nanomaterials of curcumin with hyaluronic acid accelerate the efficacy of curcumin in the treatment of various disorders like arthritis, cancer, hepatic fibrosis, neural disorders, wound healing, and skin regeneration, it is largely due to the combined effect of hyaluronic acid and curcumin. However, due to limited clinical trials and experiments on humans and animals, there is a substantial gap in research for the safety and efficacy of nanomaterials of curcumin-hyaluronic acid in the treatment of curcumin and hyaluronic acid targeted diseases and disorders. Main body of the abstract In this current review, we have first described various reported synthetic nanomaterials of curcumin-hyaluronic acid, then in the next section, we have described various fields, disorders, and diseases where these are being applied and in the final section of this review, we discussed the research gap, and future research directions needed to propose the fabricated nanocurcumin-hyaluronic acid biomaterials. Short conclusion There are substantial gaps in research for the safety and efficacy of nanomaterials of curcumin with hyaluronic acid due to limited available data of clinical trials and experiments of nanocurcumin-hyaluronic acid biomaterials on humans and animals. So, it entirely requires serious and committed efforts through the well-organized system of practical and clinical trials which provide results, data, and detections that lead to the formulation of the best drug from curcumin with hyaluronic acid for the treatment of curcumin and hyaluronic acid targeted diseases and disorders.

Download Full-text

Safety and efficacy of intra articular injections of a combination of hyaluronic acid and mannitol (HAnOX-M) in patients with symptomatic knee osteoarthritis. Results of a double-blind, controlled, multicenter, randomized trial

Osteoarthritis and Cartilage ◽

10.1016/j.joca.2016.01.966 ◽

2016 ◽

Vol 24 ◽

pp. S528

Author(s):

T. Conrozier ◽

N. Afif ◽

R. Lecurieux ◽

A. Walliser ◽

X. Chevalier

Keyword(s):

Hyaluronic Acid ◽

Knee Osteoarthritis ◽

Randomized Trial ◽

Double Blind ◽

Safety And Efficacy ◽

Multicenter Randomized Trial ◽

Symptomatic Knee Osteoarthritis ◽

Symptomatic Knee

Download Full-text

Evaluating the Safety and Efficacy of a Highly Viscous 33-mg/mL Hyaluronic Acid Volumizing Filler in the Treatment of Facial Wrinkles: An Open-Labeled, Clinical Trials

Galen Medical Journal ◽

10.31661/gmj.v8i0.1148 ◽

2019 ◽

Vol 8 ◽

pp. e1148

Author(s):

Elnaz Razavian ◽

Setareh Tehrani

Keyword(s):

Hyaluronic Acid ◽

High Volume ◽

Soft Tissue Augmentation ◽

Nodule Formation ◽

Safety And Efficacy ◽

Significant Correction ◽

Clinically Significant ◽

One Year ◽

First Time

Background: The 33-mg/mL hyaluronic acid (HA) formulation is a highly concentrated, cross-linked, cohesive, smooth, and completely reversible volumizing filler approved by Conformité Européene. For the first time, we aimed to evaluate the long-term efficacy and safety of the 33-mg/mL HA filler for soft tissue augmentation in the treatment of facial wrinkles. Materials and Methods: After optimal wrinkle correction was achieved in the patients undergoing treatment by injecting the 33-mg/mL HA filler at the injection site plus one touch-up at a 2-week interval, the safety and efficacy of the filler were assessed on the 5-point Facial Volume Loss Scale through the 1-year study period. Patients were evaluated daily for 14 days and after 6 and 12 months post-treatment. Results: A total of 86 subjects were treated. The mean wrinkle scores of the patients were 3.95+0.79 (range of 3-5) before treatment, 2.3+0.94 (range 1-5) six months after treatment, and 2.93+1.29 (range of 1-5) one year after treatment. Clinically significant mean wrinkle correction (P=0.001) was still evident at>12 months of treatment through 33-mg/mL HA formulation. A clinically significant correction at>12 months after treatment was maintained by 79% of patients. Nodule formation and swelling were more frequent when the 33-mg/mL HA filler was used compared with the use of less concentrated HA fillers. One patient developed angioedema-like swelling and induration last few months. Conclusion: The 33-mg/mL HA filler can provide long-term correction lasting for one year or more. Adverse effects, especially swelling and nodule formation were more common in this filler compared with less concentrated HA fillers. The side effects were correlated with the volume of the injected filler. We recommend using this concentration with low volume or combining high volume with lower concentration. [GMJ.2019;8:e1148]

Download Full-text

Treatment of Stress Velopharyngeal Incompetence With Injection of Hyaluronic Acid

The Cleft Palate-Craniofacial Journal ◽

10.1177/1055665617732788 ◽

2017 ◽

Vol 55 (4) ◽

pp. 615-618 ◽

Cited By ~ 1

Author(s):

Steven Koprowski ◽

Michael J. VanLue ◽

Michael E. McCormick

Keyword(s):

Hyaluronic Acid ◽

Posterior Pharyngeal Wall ◽

Clinical Entity ◽

Multidisciplinary Management ◽

Pharyngeal Wall ◽

Safety And Efficacy ◽

Velopharyngeal Incompetence ◽

Acid Compound

Stress velopharyngeal incompetence (VPI) is a challenging clinical entity that can be managed by a variety of surgical and nonsurgical approaches. We describe the case of a clarinetist who presented with nasal air escape while playing. She had successful improvement in her symptoms after targeted injection of a hyaluronic acid compound to her posterior pharyngeal wall. Our objective is to describe the safety and efficacy of this technique, to emphasize the multidisciplinary management of patients with stress VPI, and to review the importance of both nasopharyngoscopy and videofluoroscopy in their evaluation.

Download Full-text